Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of April 16, 2025, Adaptimmune Therapeutics (ADAP) has a market cap of $62.147 million USD. According to our data, Adaptimmune Therapeutics is ranked No.7911 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Apr 16, 2025 | $62.15 M |
-54.94%
|
| Dec 31, 2024 | $0.14 B |
-32.03%
|
| Dec 29, 2023 | $0.20 B |
-45.68%
|
| Dec 30, 2022 | $0.37 B |
-61.07%
|
| Dec 31, 2021 | $0.96 B |
-30.43%
|
| Dec 31, 2020 | $1.38 B |
349.17%
|
| Dec 31, 2019 | $0.31 B |
-79.13%
|
| Dec 31, 2018 | $1.47 B |
-13.92%
|
| Dec 29, 2017 | $1.71 B |
64.94%
|
| Dec 30, 2016 | $1.04 B |
-66.42%
|
| Dec 31, 2015 | $3.09 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Gilead Sciences
GILD
|
$131.74 B |
-0.002 M
|
USA
|
 Novartis
NVS
|
$218.28 B |
1.163 B
|
Switzerland
|
 Bristol-Myers Squibb
BMY
|
$101.74 B |
-0.001 M
|
USA
|
 Amgen
AMGN
|
$158.77 B |
0.132 B
|
USA
|
 Pfizer
PFE
|
$127.27 B |
-0.003 M
|
USA
|
 Merck
MRK
|
$197.26 B |
0.003 M
|
USA
|
 Johnson & Johnson
JNJ
|
$370.20 B |
0.003 M
|
USA
|
 Regeneron Pharmaceuticals
REGN
|
$60.99 B |
1.014 B
|
USA
|
 AstraZeneca
AZN
|
$210.42 B |
-0.005 M
|
UK
|
 GlaxoSmithKline
GSK
|
$72.32 B |
0.003 M
|
UK
|
 Sanofi
SNY
|
$127.25 B |
3.672 B
|
France
|
 Biogen
BIIB
|
$17.12 B |
0.000 M
|
USA
|
 Eli Lilly
LLY
|
$679.94 B |
-0.022 M
|
USA
|
| Market Cap | = | ADAP Stock Price | * | ADAP Shares Outstanding |
| = | $0.24 | * | 0.26 B | |
| = | $62.15 M |